Advertisement

Dementia complicating type 2 diabetes and the influence of premature mortality: the Fremantle Diabetes Study

  • David G. BruceEmail author
  • Timothy M. E. Davis
  • Wendy A. Davis
Original Article
  • 40 Downloads
Part of the following topical collections:
  1. Pregnancy and diabetes

Abstract

Aims

To investigate risk factors for, and the influence of premature mortality on, dementia complicating type 2 diabetes.

Methods

Participants with type 2 diabetes in the community-based observational Fremantle Diabetes Study Phase 1 (n = 1291, mean age 64.0 years) were followed from 1993 to 1996 to end-June 2012. Incident dementia was identified from validated health databases. Dementia risk was assessed using Cox proportional hazards modelling supplemented by competing risk regression modelling in the total cohort and sub-groups defined by age of diabetes onset as mid-life (< 65 years) or late-life (≥ 65 years).

Results

During mean ± SD follow-up of 12.7 ± 5.9 years, 717 participants (55.5%) died and 180 (13.9%) developed dementia. Overall, few risk factors predicted incident dementia and most predicted time to death. In mid-life diabetes, incident dementia was predicted by diabetes duration, cerebrovascular disease, schizophrenia, antipsychotic medication and the APOE ε4 allele. In late-life diabetes, risk factors were peripheral neuropathy, lack of exercise, lower fasting serum glucose, no antihypertensive therapy and the APOE ε4 allele. Competing risk analysis showed age to be a positive predictor compared with the inverse association in Cox models that suggested survivor bias in an older community-based cohort.

Conclusions

Dementia in type 2 diabetes is multifactorial. An association with diabetes duration, independent of most possible confounders, suggests that one or more unmeasured processes specific to diabetes may be implicated in the pathogenesis. The risk factors for dementia were also associated with an increased risk of death. This suggests that recently reported improvements in mortality in type 2 diabetes may be accompanied by reductions in dementia incidence.

Keywords

Type 2 diabetes Dementia Longitudinal study Cohort study 

Notes

Acknowledgements

The authors thank the Fremantle Diabetes Study staff, investigators, and participants, and the staff at the Western Australian Data Linkage Branch.

Funding

This work was supported by the Raine Foundation of the University of Western Australia and the Fremantle Hospital Medical Research Foundation. TMED was supported by a National Health and Medical Research Council of Australia Practitioner Fellowship (Grant number 1058260). The study sponsors had no role in the design, methods, recruitment of participants, data collection, analysis or preparation of the paper.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Human and animal rights

All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2008 (5).

Informed consent

Informed consent was obtained from all patients for being included in the study.

Supplementary material

592_2019_1322_MOESM1_ESM.docx (49 kb)
Supplementary material 1 (DOCX 49 KB)

References

  1. 1.
    Exalto LG, Whitmer RA, Kappele LJ et al (2012) An update on type 2 diabetes, vascular dementia and Alzheimer’s disease. Exp Gerontol 47:858–864CrossRefGoogle Scholar
  2. 2.
    Feinkohl I, Price JF, Strachan MW et al (2015) The impact of diabetes on cognitive decline: potential vascular, metabolic, and psychosocial risk factors. Alzheimer’s Res Ther 7:46CrossRefGoogle Scholar
  3. 3.
    Peila R, Rodriguez BL, Launer LJ et al (2002) Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: the Honolulu-Asia Aging Study. Diabetes 51:1256–1262CrossRefGoogle Scholar
  4. 4.
    Sullivan MD, Katon WJ, Lovato LC et al (2013) Association of depression with accelerated cognitive decline among patients with type 2 diabetes in the ACCORD-MIND trial. JAMA Psychiatry 70:1041–1047CrossRefGoogle Scholar
  5. 5.
    Jacobs V, Cutler MJ, Day JD et al (2015) Atrial fibrillation and dementia. Trends Cardiovasc Med 25:44–51CrossRefGoogle Scholar
  6. 6.
    Qiu C, Winblad B, Marengoni A et al (2006) Heart failure and risk of dementia and Alzheimer disease: a population-based cohort study. Arch Intern Med 166:1003–1008CrossRefGoogle Scholar
  7. 7.
    Rusanen M, Ngandu T, Laatikainen T et al (2013) Chronic obstructive pulmonary disease and asthma and the risk of mild cognitive impairment and dementia: a population based CAIDE study. Curr Alzheimer Res 10:549–555CrossRefGoogle Scholar
  8. 8.
    Zilkens RR, Bruce DG, Duke J et al Semmens JB (2014) Severe psychiatric disorders in mid-life and risk of dementia in late- life (age 65–84 years): a population based case-control study. Curr Alzheimer Res 11:681–693CrossRefGoogle Scholar
  9. 9.
    Turner RC, Cull CA, Frighi V et al (1999) Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA 281:2005–2012CrossRefGoogle Scholar
  10. 10.
    Davis TME, Brown SGA, Jacobs IG et al (2010) Determinants of severe hypoglycemia complicating type 2 diabetes: the fremantle diabetes study. J Clin Endocrinol Metab 95:2240CrossRefGoogle Scholar
  11. 11.
    Zilkens RR, Davis WA, Spilsbury K et al (2013) Earlier age of dementia onset and shorter survival times in dementia patients with diabetes. Am J Epidemiol 177:1246–1254CrossRefGoogle Scholar
  12. 12.
    Xu W, Qiu C, Gatz M et al (2009) Mid- and late-life diabetes in relation to the risk of dementia: a population-based twin study. Diabetes 58:71–77CrossRefGoogle Scholar
  13. 13.
    Bruce DG, Davis WA, Starkstein SE et al (2014) Mid-life predictors of cognitive impairment and dementia in type 2 diabetes mellitus: the Fremantle Diabetes Study. J Alzheimers Dis 42(Suppl 3):S63–S70CrossRefGoogle Scholar
  14. 14.
    Emerging Risk Factors C, Seshasai SR, Kaptoge S et al (2011) Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med 364:829–841CrossRefGoogle Scholar
  15. 15.
    Davis WA, Zilkens RR, Starkstein SE et al (2017) Dementia onset, incidence and risk in type 2 diabetes: a matched cohort study with the Fremantle Diabetes Study Phase I. Diabetologia 60:89–97CrossRefGoogle Scholar
  16. 16.
    Koller MT, Raatz H, Steyerberg EW et al (2012) Competing risks and the clinical community: irrelevance or ignorance? Stat Med 31:1089–1097CrossRefGoogle Scholar
  17. 17.
    Davis TM, Bruce DG, Davis WA (2013) Cohort profile: the Fremantle Diabetes Study. Int J Epidemiol 42:412–421CrossRefGoogle Scholar
  18. 18.
    Holman CD, Bass AJ, Rouse IL et al (1999) Population-based linkage of health records in Western Australia: development of a health services research linked database. Aust N Z J Public Health 23:453–459CrossRefGoogle Scholar
  19. 19.
    Levey AS, Stevens LA, Schmid CH et al (2009) A new equation to estimate glomerular filtration rate. Ann Intern Med 150:604–612CrossRefGoogle Scholar
  20. 20.
    Norman PE, Davis WA, Bruce DG et al (2006) Peripheral arterial disease and risk of cardiac death in type 2 diabetes. Diabetes Care 29:575CrossRefGoogle Scholar
  21. 21.
    Bruce D, Davis W, Starkstein S et al (2005) A prospective study of depression and mortality in patients with type 2 diabetes: the Fremantle Diabetes Study. Diabetologia 48:2532–2539CrossRefGoogle Scholar
  22. 22.
    Zilkens RR, Spilsbury K, Bruce DG et al (2009) Linkage of hospital and death records increased identification of dementia cases and death rate estimates. Neuroepidemiology 32:61–69CrossRefGoogle Scholar
  23. 23.
    Lau B, Cole SR, Gange SJ (2009) Competing risk regression models for epidemiologic data. Am J Epidemiol 170:244–256CrossRefGoogle Scholar
  24. 24.
    Latouche A, Allignol A, Beyersmann J et al (2013) A competing risks analysis should report results on all cause-specific hazards and cumulative incidence functions. J Clin Epidemiol 66:648–653CrossRefGoogle Scholar
  25. 25.
    Thiebaut AC, Benichou J (2004) Choice of time-scale in Cox’s model analysis of epidemiologic cohort data: a simulation study. Stat Med 23:3803–3820CrossRefGoogle Scholar
  26. 26.
    Zlokovic BV (2011) Neurovascular pathways to neurodegeneration in Alzheimer’s disease and other disorders. Nat Rev Neurosci 12:723–738CrossRefGoogle Scholar
  27. 27.
    De Felice FG, Ferreira ST (2014) Inflammation, defective insulin signaling, and mitochondrial dysfunction as common molecular denominators connecting type 2 diabetes to Alzheimer disease. Diabetes 63:2262–2272CrossRefGoogle Scholar
  28. 28.
    Serrano-Pozo A, Qian J, Monsell SE et al (2015) APOEepsilon2 is associated with milder clinical and pathological Alzheimer disease. Ann Neurol 77:917–929CrossRefGoogle Scholar
  29. 29.
    Luitse MJ, Biessels GJ, Rutten GE et al (2012) Diabetes, hyperglycaemia, and acute ischaemic stroke. Lancet Neurol 11:261–271CrossRefGoogle Scholar
  30. 30.
    Douglas IJ, Smeeth L (2008) Exposure to antipsychotics and risk of stroke: self controlled case series study. BMJ 337:a1227CrossRefGoogle Scholar
  31. 31.
    Brownrigg JR, Hughes CO, Burleigh D et al (2016) Microvascular disease and risk of cardiovascular events among individuals with type 2 diabetes: a population-level cohort study. Lancet Diabetes Endocrinol 4:588–597CrossRefGoogle Scholar
  32. 32.
    Du X, Ninomiya T, de Galan B et al (2009) Risks of cardiovascular events and effects of routine blood pressure lowering among patients with type 2 diabetes and atrial fibrillation: results of the ADVANCE study. Eur Heart J 30:1128–1135CrossRefGoogle Scholar
  33. 33.
    Gregg EW, Li Y, Wang J et al (2014) Changes in diabetes-related complications in the United States, 1990–2010. N Engl J Med 370:1514–1523CrossRefGoogle Scholar
  34. 34.
    Wu YT, Fratiglioni L, Matthews FE et al (2015) Dementia in western Europe: epidemiological evidence and implications for policy making. Lancet Neurol 15:116–124CrossRefGoogle Scholar
  35. 35.
    Bugnicourt JM, Godefroy O, Chillon JM et al (2013) Cognitive disorders and dementia in CKD: the neglected kidney-brain axis. J Am Soc of Nephrol JASN 24:353–363CrossRefGoogle Scholar
  36. 36.
    Davis TM, Chubb SA, Davis WA (2016) The relationship between estimated glomerular filtration rate trajectory and all-cause mortality in type 2 diabetes: the Fremantle Diabetes Study. Eur J Endocrinol 175:273–285CrossRefGoogle Scholar
  37. 37.
    Phung TK, Andersen BB, Hogh P et al (2007) Validity of dementia diagnoses in the Danish hospital registers. Dement Geriatr Cogn Disord 24:220–228CrossRefGoogle Scholar
  38. 38.
    Henderson T, Shepheard J, Sundararajan V (2006) Quality of diagnosis and procedure coding in ICD-10 administrative data. Med Care 44:1011–1019CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Italia S.r.l., part of Springer Nature 2019

Authors and Affiliations

  1. 1.Medical School, Fremantle HospitalUniversity of Western AustraliaFremantleAustralia

Personalised recommendations